Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
- Authors
- Jung, Seung Il; Kim, Myung Soo; Jeong, Chang Wook; Kwak, Cheol; Hong, Sung Kyu; Kang, Seok Ho; Joung, Jae Young; Lee, Seung Hwan; Yun, Seok Joong; Kim, Tae-Hwan; Park, Sung Woo; Jeon, Seong Soo; Kang, Minyong; Lee, Ji Youl; Chung, Byung Ha; Hong, Jun Hyuk; Ahn, Hanjong; Kim, Choung-Soo; Kwon, Dong Deuk
- Issue Date
- 1월-2020
- Publisher
- KOREAN UROLOGICAL ASSOC
- Keywords
- Androgen antagonists; Neoplasm metastasis; Prostate neoplasms; Treatment outcome
- Citation
- INVESTIGATIVE AND CLINICAL UROLOGY, v.61, no.1, pp.19 - 27
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- INVESTIGATIVE AND CLINICAL UROLOGY
- Volume
- 61
- Number
- 1
- Start Page
- 19
- End Page
- 27
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/58531
- DOI
- 10.4111/icu.2020.61.1.19
- ISSN
- 2466-0493
- Abstract
- Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naive patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score >= 8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125-0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naive patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.